Clinical Trials
3
Active:0
Completed:1
Trial Phases
3 Phases
Phase 1:1
Phase 4:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (33.3%)Phase 1
1 (33.3%)Phase 4
1 (33.3%)Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF
Not Applicable
Terminated
- Conditions
- Retinal Vein Occlusion (RVO)Macular Edema
- Interventions
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Retina Research Institute, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT01946399
- Locations
- 🇺🇸
The Retina Institute, Saint Louis, Missouri, United States
Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
Phase 4
- Conditions
- Age Related Macular Degeneration
- Interventions
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- Retina Research Institute, LLC
- Target Recruit Count
- 22
- Registration Number
- NCT01657669
- Locations
- 🇺🇸
The Retina Institute, Saint Louis, Missouri, United States
🇺🇸Valley Retina Institute, McAllen, Texas, United States
Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome
Phase 1
Completed
- Conditions
- Choroidal NeovascularizationPresumed Ocular Histoplasmosis
- Interventions
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Retina Research Institute, LLC
- Target Recruit Count
- 5
- Registration Number
- NCT01578720
- Locations
- 🇺🇸
The Retina Institute, Saint Louis, Missouri, United States
News
No news found